Neratinib, a clinical drug against breast cancer, protects against atherosclerosis via ASK1 inhibition
Fan-shun Zhang, Chenyang He, Yanjun Yin, Zhihua Wang, Xiumei Wu, Danielle Kamato, Ruixue Leng, Jiang‐Yun Luo, Jianping Weng, Suowen Xu
Neratinib reduces atherosclerosis by inhibiting ASK1-mediated endothelial inflammation, showing potential as a repurposed drug for vascular disease.
Circulation Research · Jan 9, 2026Peer-reviewedPharmacology & Toxicology